...
首页> 外文期刊>Frontiers in Oncology >Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
【24h】

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

机译:Exon 19-Del-Egfr突变体肺腺癌的同时AFATINIB和全脑放射治疗:一个案例报告和对文献的迷你审查

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung cancer cases with an increased incidence in adenocarcinoma, and approximately one-third of patients will present with concomitant brain metastases. We report the case of a 50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma who progressed on second-generation TKI therapy with manifestation of symptomatic simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib resulted in an almost complete regression of neurological symptoms as well as good, durable radiological response. Furthermore, treatment was well tolerated with no relevant adverse effects.
机译:在大约3.8%的非小细胞肺癌病例中发现百分症转移(LM)在腺癌发病率增加,约有三分之一的患者将存在于伴随的脑转移。我们举报了50岁的男性患者,患有IV阶段19-Del-EGFR突变体肺腺癌,其在第二代TKI治疗中进行了症状同时弥漫性大脑和LM的表现。与同时AFATINIB的全脑放射治疗导致神经系统症状的几乎完全回归,以及良好,耐用的放射反应。此外,治疗良好耐受,没有相关的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号